ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2414

Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Abstract Number: 2059

Autoantibody Patterns in Myositis Immunoblot Testing: A Retrospective Study inInflammatory Myopathies and Connective Tissue Diseases (2017–2023)
Abstract Number: 2492

Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort
Abstract Number: 2295

Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Abstract Number: 2382

Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Abstract Number: 1476

Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
Abstract Number: 0250

Autoinflammatory diseases in adult patients. Spanish registry.
Abstract Number: 0323

Automated Effusion-Synovitis Volume is Prognostic and Responsive to Knee Osteoarthritis Progression: Data from the Osteoarthritis Initiative
Abstract Number: 2471

Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
Abstract Number: 2612

Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
Abstract Number: 2172

Automating the Curation and Summarization of Rheumatology Fellowship Applications using Generative AI Agents and Transformer Models
Abstract Number: 2505

Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
Abstract Number: 2213

Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases
Abstract Number: 1753

Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Abstract Number: 1374

AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].